| Article Access Statistics|
| Viewed||1838 |
| Printed||19 |
| Emailed||0 |
| PDF Downloaded||491 |
| Comments ||[Add] |
Click on image for details.
CLINICAL PRACTICE GUIDELINES
|Year : 2019
: 61 | Issue : 8 | Page
|Clinical practice guidelines for the assessment and management of attention-deficit/hyperactivity disorder
Ruchita Shah, Sandeep Grover, Ajit Avasthi
Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Click here for correspondence address and
|Date of Web Publication||14-Jan-2019|
|How to cite this article:|
Shah R, Grover S, Avasthi A. Clinical practice guidelines for the assessment and management of attention-deficit/hyperactivity disorder. Indian J Psychiatry 2019;61, Suppl S2:176-93
|How to cite this URL:|
Shah R, Grover S, Avasthi A. Clinical practice guidelines for the assessment and management of attention-deficit/hyperactivity disorder. Indian J Psychiatry [serial online] 2019 [cited 2019 Dec 7];61, Suppl S2:176-93. Available from: http://www.indianjpsychiatry.org/text.asp?2019/61/8/176/250041
| Introduction|| |
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood psychiatric disorders. ADHD affects around 5%–7% of school-aged children. It is a neurodevelopmental disorder that runs a chronic course and causes significant impairments across various domains of everyday functioning, such as peer and social functioning, academic functioning, and occupational functioning across the lifespan. Besides the patient, ADHD also has significant negative impact on the caregivers. This guideline seeks to lay out guidelines for effective and comprehensive assessment, diagnosis, and management of ADHD. It attempts to update the previous guidelines taking into account the current state of evidence that can inform clinical practice. These guidelines ought to be read in conjunction with the earlier version of the treatment guidelines on ADHD as developed and published by the Indian Psychiatric Society in 2007.
| Scope of This Document|| |
This guideline provides a framework for diagnosis and management of ADHD in children and adolescents aged up to 18 years. In this document, the terms “child” and “children” represent all individuals below 18 years of age, unless specified otherwise. The term “adolescent” represents individuals between 13 and 18 years of age. The term “preschoolers” is used to indicate individuals who are below 6 years of age. These guidelines may not be applicable to adult patients who have ADHD as their treatment needs may be different. Finally, it is expected that recommendations made will have to be tailored to suit the needs of individual patients.
| Assessment and Evaluation|| |
A comprehensive assessment including detailed history, mental state, and physical examination is needed to reach the diagnosis and estimate the severity and impact of the disorder on the patient and caregivers. Comorbid developmental, psychiatric, and medical disorders and psychosocial or environmental factors such as family discord, parenting, and parental substance abuse that are directly relevant to the management should be assessed as far as possible. [Table 1] presents the components of a comprehensive assessment, and [Table 2] shows the clinical questions that need to be answered while undertaking the process of assessment.
|Table 1: Components of a comprehensive assessment and evaluation (text in parenthesis may be used as a guide for assessment)|
Click here to view
The assessment of preschoolers, children, and adolescents for ADHD comprises clinical interviews with parents and the patient, as well as obtaining information directly or indirectly (through parent accounts) from other relevant sources and settings including preschool, daycare, and school. Information from teachers may be obtained by requesting for teacher observation reports (unstructured) or teacher ratings on a structured rating scale (See Rating scales Section). Such requests should be sent through parents after explaining to them the need for such information and seeking their and the child's explicit consent and assent. Parents or the child may be reluctant to initiate such a communication for several reasons, the most important being fear of the child being stigmatized. Clinicians must, as far as possible, explain to the parents the need of teacher report and how this can aid in assessment, diagnosis, and management. If the child and parents are still reluctant, then the clinicians may satisfy themselves through parent and child accounts of symptoms and functioning in the school setting and review of school work and report cards. Further, in the Indian context, the clinician may involve other family members such as grandparents, especially if the child resides in a joint or an extended family. This will provide additional important information, opportunities to understand methods the family uses to handle the problematic behaviors, and expectations and perceptions regarding and treatment of these behaviors.
It is important to remember that the histories may vary considerably depending on the informants' own perceptions regarding and tolerance toward such behaviors, their awareness, and opportunities for observations. The histories from different sources may complement each other to provide a more complete and realistic picture; hence, multi-informant interviews seeking information across various domains of functioning and in various settings are the key.
The process of assessment may require more than one visit. It is an ongoing process, which as far as possible must be continued to be based on multi-informant accounts across multiple settings as for the initial assessment, and it should focus on changing needs of the patient and the family.
The diagnosis should preferably be based on the diagnostic criteria as per prevailing nosological systems for the symptoms of inattention, hyperactivity, and impulsivity. While establishing the diagnostic criteria – age of onset, persistence, and duration of the symptoms must be taken into account. When symptoms are of relatively recent onset, other psychiatric disorders such as mood or psychotic disorders that may mimic ADHD must be considered. The symptoms must be developmentally inappropriate; it is suggested that the clinician assess the developmental history thoroughly and make a working clinical impression of the mental age of the child or adolescent. When intellectual subnormality is known or suspected, the rule of thumb is that the symptoms should be inappropriate for the mental age to consider ADHD. Another related consideration is that as a child grows, symptom manifestations may change. Preschoolers with ADHD are highly overactive (described as “whirlwind”), do not listen to when called, have no sense of danger, and have short play sequences (of <3 min), and often leave activities incomplete. As a child reaches primary school, he/she is found to have difficulty remaining still or calm in situations where he/she is expected to remain so; for example, in assembly halls and classrooms. Inattention is manifested by brief activities of <10 min, being forgetful, disorganized, and easily distractible. Impulsivity is seen in the form of acting out of turn, interrupting other children, thoughtless rule breaking, intrusions on peers, and getting into accidents. During adolescence, the over-activity presents more as inner restlessness and some fidgetiness instead of the manifest over-activity seen during preschool and early childhood years. Inattention, on the other hand, may manifest as difficulties in organizing tasks, procrastination, and frequent missing of deadlines. Impulsivity may manifest as risk-taking and substance use. Thus, adolescents may present with problems mainly related to inattention and impulsivity, and a thorough developmental history that traces the symptoms from their onset during childhood may help clarify the diagnosis. Several symptoms are present in two or more settings such as at home, school or preschool, family, and friends. It may be borne in mind that the symptomatic manifestations can vary considerably depending on the context in a given setting. [Table 3] shows the factors that can affect symptoms of ADHD.
Next, it is important to assess the impairment caused by the symptoms in different domains of functioning including social and interpersonal, academic or occupational, and legal domains. In fact, for the diagnosis, it is required that the symptoms should cause impairment in at least one domain. The clinician must attempt to make an overall impression of the severity of ADHD based on the severity and number of symptoms and severity of impairments caused by the symptoms. In addition, there may be some associated problems that should not, by themselves, be used as evidence for ADHD, but if present alongside need to be taken into account while planning management. These problems include defiant or noncompliant behaviors, irritability, mood swings, aggression, temper tantrums, sleep difficulties, clumsiness, mild delays in speech and language, and substance abuse or high-risk behaviors.
The clinician must, as far as possible also, assess for the potential effects that ADHD symptoms can have on development. Such effects are seen in cognitive development and academic achievements (for example, chronic inattentiveness leads to years of inadequate learning and hence affects adversely further learning), social development (children with ADHD may be inattentive to social cues, are impulsive during their interactions with peers, and occasionally have lesser opportunities needed for peer interactions due to peer rejection; these all lead to inadequate social development, manifesting as social immaturity), development of self-esteem and self-identity (peer rejection, rejection by adults, and constant criticism may all affect the development of self-esteem and identity though many of these children may appear boisterous).
Differential diagnosis and comorbidities
It is important to note that the same disorder may be a differential diagnosis or may even be a comorbid disorder. [Table 4] summarizes the comorbidities seen with ADHD. [Table 5] presents clinical points to differentiate ADHD from other developmental and psychiatric disorders. The clinician must as far as possible enquire into developmental and current and past psychiatric history.
|Table 4: Comorbidities seen with attention-deficit/hyperactivity disorder|
Click here to view
|Table 5: Clinical features for differentiating attention-deficit/hyperactivity disorder from other disorders|
Click here to view
In case of preschoolers, clinicians must also bear in mind that the so-called symptoms may be developmentally normal or may represent the temperamental characteristics of the child. In the latter case, the clinician should refrain from diagnosing ADHD but offer parent training for managing difficult behaviors (See Management Section; Formulating a Treatment Plan for preschoolers). Substance use history should be enquired into, especially while assessing older children and adolescents. This history may be taken from the adolescent by ensuring privacy (See Mental State Examination Section).
It is suggested that the clinician be aware of the problem of diagnostic overshadowing, i.e., symptoms of another disorder are mistakenly subsumed as manifestations of the primary disorder. For example, in a child with hyperactivity and impulsivity with mild intellectual disability, the symptoms are considered to be due to the latter although they are clearly developmentally inappropriate. The clinicians must also recognize the problem of overdiagnosis in the presence of other disorders. For example, a child with autism spectrum disorder (ASD) is diagnosed with ADHD, when the symptoms of inattention and hyperactivity are mainly related to social communication and sensory issues of ASD. Detailed and focused clinical interviewing and collecting information across various situations and domains will help the clinician in such circumstances.
[Table 6] presents the key clinical points to guide the process of establishing the diagnosis.
|Table 6: Key clinical points to guide the process of establishing the diagnosis|
Click here to view
Rarely, medical disorders may present with behaviors resembling ADHD. Such ADHD-like problems may be secondary to head injury, wherein inattention is prominent, thyroid disorders, and absence seizures. Rarely, ADHD-like symptoms may be present in genetic syndromes such as fragile X or may be secondary to certain medications such as bronchodilators, thyroxine, neuroleptics (causing akathisia), and isoniazid. Epilepsy may be comorbid especially in children with comorbid neurodevelopmental disorders such as intellectual disability. The clinician must also take specific medical history before prescribing any drug. This should include a history of syncope or fainting episodes, exercise intolerance, congenital cardiac malformations, or any cardiac surgery.
Mental state examination
Mental state examination of a preschooler or a young child may be carried out concurrently with parent interview. It is important that the clinicians equip themselves with age-appropriate play and work materials that would help in building rapport as well as engaging the child in an age-appropriate activity. During such observations and interactions, it is suggested clinicians attempt to gauge the general intellectual capacity of the child, language development, and verbal and nonverbal communication. The clinician may or may not find evidence of overactivity, impulsivity, and inattention during the time of interview as children may perform better when they find tasks interesting or the situation is structured with one-to-one adult interaction as in the clinic. This should not be taken as evidence of absence of ADHD. Further, younger children might not be aware of their problems. Clinicians, therefore, should not rely solely on their observations and interview with younger children for diagnosing ADHD. Rather, clinicians may use this opportunity to observe for coexisting disorders including intellectual subnormality, as well as to observe child–parent interactions. It may reveal overprotective, hostile, and critical parent–child interactions and parents' styles of responding to defiance.
It is desirable that older children and adolescents also be interviewed separately from their parents; this acknowledges their need for autonomy and confidentiality. Adolescents may downplay their problems and its impact on their functioning. Hence, the clinician need not focus on ADHD symptoms but may rather interview the child/adolescent regarding depressive symptoms and suicidal ideation, peer relations, and bullying. Mental state examination should include a formal assessment of form and content of thought, presence of delusions, hallucinations, depressive cognitions, worries, ruminations, and obsessive symptoms as far as possible. There may be evidence of low self-esteem despite apparent boisterousness. Substance use history should be elicited, and history related to other high-risk behaviors may be elicited if overall history is indicative of the same. However, such assessments should preferably not be done before a working therapeutic relationship has been established with the adolescent or child.
Rating scales and screening instruments may assist in the diagnostic process, but these are neither necessary nor can these replace a good clinical assessment. These include Conner's parent and teacher rating scales, Vanderbilt parent and teacher rating scales, and ADHD rating scale–fourth edition. These can be helpful in acquiring structured information from other sources such as teachers. Besides, the rating scales may assist in monitoring treatment response. The scales may over- or under-diagnose ADHD when comorbid intellectual disability or ASD is present. Most of the rating scales are expensive and do not have Indian norms; hence, it might be difficult to use these in routine clinical practice. However, more generic instruments such as Strengths and Difficulties Questionnaire and Achenbach's Child Behavior Checklist may be more easily accessible. The clinical global impression (CGI) scales and children's global assessment of functioning scale may be used for baseline assessments and further monitoring.
Routine psychological testing is not indicated. If intellectual disability is suspected, Intelligence quotient (IQ) testing may be conducted. However, in case of severe symptoms, the scores may be erroneously low, and hence, test must be repeated after adequate symptom control. Similarly, if specific learning disorder is suspected, the psychological assessment for the same should be carried out after adequate control of ADHD symptom. Playroom observation may be assistive when carried out by an experienced clinician. However, it is neither mandatory nor replaces a thorough clinical evaluation. Similarly, neuropsychological tests such as continuous performance tests are not indicated in routine clinical practice.
No specific physical investigations are needed or indicated to diagnose ADHD. Neuroimaging (computed tomography [CT] scan, magnetic resonance imaging, positron emission tomography, and single photon emission CT scans) and electroencephalography should not be carried out without any specific clinical indication. In cases where lead toxicity is suspected, i.e., when history reveals exposure to lead plumbing or high lead levels in the environment, lead levels should be checked. Thyroid profile should be tested only when clinical features are suggestive of a thyroid disorder.
| Formulating a Treatment Plan|| |
For a comprehensive treatment plan, factors that need to be taken into account are age and developmental stage of the child, severity of symptoms, domains of functioning affected, how symptoms affect or may affect everyday life, comorbid developmental, psychiatric, and medical disorders, psychosocial risk factors and protective factors, and goals and resources or assets within the child and family. The plan must address as far as possible the child's current psychological, behavioral, and educational needs. It is suggested that needs assessment be an ongoing process as needs may change over time. Regular discussions with the children and their family must be carried out to the extent possible regarding the same. [Table 7] presents the guiding principles for a comprehensive treatment plan.
|Table 7: Principles to guide formulation of a comprehensive treatment plan|
Click here to view
Before starting any treatment for ADHD, it is important to build a working therapeutic alliance with the child and family, take their accounts of perceptions and preferences regarding treatment, and offer them information regarding diagnosis and treatment.
The first step toward management is building a good therapeutic alliance with the child or adolescent and the family. Positive regard for the family's perceptions and concerns is needed. Parents' perceptions regarding diagnosis and treatment may be influenced by other family members, friends, teachers, media, and other physicians and may differ from the clinician's opinion. These perceptions may influence treatment preferences as well as adherence to treatment. For example, parents who consider the behaviors diagnosed as ADHD to be “normal naughty behavior” or due to the child “being lazy” may request for only “counseling” to the child and may not consider medication or parent training as necessary. Family's concerns regarding side effects and weighing of risk–benefit may not match with that of the clinician's. Inadequate adherence on the prescribed treatment may occur due to any of these reasons, leading to nonresponse and potentially a breach in alliance and treatment drop-out. Parental expectations from treatment also vary. For example, parents of children with ADHD and comorbid conduct disorder may expect complete resolution of all the symptoms with medication and may find the treatment ineffective when such expectations are not realized, again leading to treatment drop-out. The clinician may take into account that the needs identified by the parents and the patient may be often different. For example, the parents may be more concerned about academic performance, while the child may not identify this as an area of concern. Hence, the clinician must as far as possible make an effort to establish alliance with both the child and his parents and take into account their perceptions, preferences, and expectations. Parents have often been blamed by family, friends, or teachers for their child's behaviors or difficulties. They are often emotionally drained and experience burn-out by the time the child is brought to the clinic. The clinician must not blame the parents, must validate their positive and negative experiences with the school, extended family and professional agencies including doctors, and offer support. A good therapeutic alliance coupled with psychoeducation will help the child and parents take informed treatment decisions. Factors which can enhance therapeutic alliance are shown in [Table 8].
|Table 8: Important points to remember while building therapeutic alliance|
Click here to view
Communication of diagnosis
Before communicating the diagnosis, the clinician may as a minimum ask the parents and other significant family members about their perceptions regarding the causation of the problem behaviors. The clinician may present the diagnosis as a “brain disorder” or a “neurodevelopmental disorder” with both genetic and environmental influences. The clinician may also briefly present the psychosocial factors that can potentially influence the course and outcome of the disorder (e.g., highly inconsistent parenting, severe family discord). Further, the clinician must as far as possible address guilt and blame among the parents and address the misconceptions regarding ADHD. It may be followed by detailed psychoeducation. Furthermore, the clinician must communicate any comorbid diagnosis, if present. This is essential as treatment considerations and overall course and prognosis may vary depending upon such comorbidities. It is not uncommon in clinical practice, for parents to feel stigmatized that their child has been given a diagnostic label, and these parents and patients are often apprehensive of and reluctant to liaise with the school, fearing that the child will be labeled by the teachers. Such anticipations are often true in the child's given circumstances. The clinician must acknowledge the same while communicating the diagnosis and educating the child and parents. The clinician must preferably not communicate the diagnosis to the school without the consent of the patient and parents, even if the child was referred to the clinic by the school.
Psychoeducation may be carried out over 2–3 sessions and should as far as possible be tailored for a given child and the family. The clinician may involve any other significant family members during these sessions or may conduct psychoeducation later with them as and when such need is identified. [Table 9] presents the rationale for involving extended family members in our context.
|Table 9: Rationale for involving extended family members in the Indian context|
Click here to view
Psychoeducation may begin by asking the patient and his family regarding their own understanding of symptoms, their causation, and their beliefs regarding treatments. Psychoeducation may cover detailed description of core symptoms of hyperactivity/impulsivity and inattention and organizational difficulties, including difficulties keeping track of time, poor planning and time management, associated genetic and environmental factors such as pre- or peri-natal factors, misconceptions regarding ADHD, including that the symptoms are merely due to child's laziness or lack of motivation and available treatment modalities; both pharmacological and nonpharmacological with benefits and risks of each modality. The basic components that may be covered in psychoeducation sessions are given in [Table 10].
| Treatment Options for Management of Attention-Deficit/hyperactivity Disorder|| |
As with other psychiatric disorders, the treatment options are broadly categorized as nonpharmacological measures, pharmacological interventions, and other treatments [Table 11].
|Table 11: Modalities of intervention for attention-deficit/hyperactivity disorder|
Click here to view
Despite the evidence for short-term efficacy of medications, treatment with medications has some limitations; partial or no response in a proportion of cases, side effects, not well-proven long-term efficacy and cost-effectiveness, poor adherence, and negative perceptions of family and professionals toward medications. Nonpharmacological interventions, on the other hand, if implemented properly and adherently, may produce benefits in symptoms as well as functioning in different domains.
Environmental modifications include changes made in the environment in one or preferably more settings to either decrease the symptom manifestations or importantly decrease the impact of the symptoms. Such modifications should help enhance the performance and functioning of the child.
Such modifications include introducing structure and routine in the child's life. The daily routines such as those related to getting up and getting ready for school, on returning from school, mealtimes, and bedtime must be made regular and predictable. The child must be informed in advance of any change in the schedule as well as given reminders during transition. The physical environment must also be structured with “a place for everything.” Allot a fixed place for almost everything in the house and particularly for belongings of the patient. Use of verbal prompts and visual cues may be necessary for effective implementation. Parents can help the child in planning and managing their time through use of daily and weekly planners; sticking planners in prominent places such as in the bedroom or near the study table; labeling “places where things go” (e.g., on bookshelf) and by giving verbal or visual (or both) reminders 3–5 min before a transition in routine. For example, the parent may say “5 min are left for playing your game” or “after 5 min, we will start with Maths.” Classrooms are ordinarily more structured as compared to home, and the routines are better defined. The teachers can use visual and verbal reminders and praise to reinforce the same.
Adult supervision may help the child, especially when on boring or mentally demanding tasks such as homework. The parent or teacher may give a simple reminder to the child when he/she goes off task. Such reminder may be verbal or physical or both; e.g., a tap on the shoulder and telling him, “Read the fifth question” or asking him, “so, where were we?”
While studying, minimize distractions around; e.g., make the child sit away from traffic, away from the TV room. The study table may be in the corner of the room, away from the windows and doors (preferably child's back facing the door), with only the books, which the child is supposed to read at that time with no other distraction on the table, with no distraction on the walls which are being faced by the child and no other child in the room to distract the child. The house should be as quiet as possible. The parent/supervisor should preferably sit with the child. The presence of toys and other screen media around should be avoided. Parents may increase stimulation of the material related to task to improve attention through use of highlighters, i.e., use colors to highlight important points. If listening to any genre of instrumental music helps the child improve his/her on-task attention, it may be tried.
Children may be provided with break times in the middle of lengthy or boring tasks. The break may be of around 5 min after every 15–20 min of being on-task or lesser in younger children or when the adult senses increase in fidgetiness. The parent may request the child to carry out a household chore such as fetching water or shoveling or any task that helps the child use his/her physical energy. In school, the teacher may ask the child to distribute copies or fetching something from the other classroom. Children may also be allowed to stand and work if that helps them to remain on-task. The child must be given adequate opportunities to channelize their excessive energy, for example, by participating in physical sports such as cycling, running, swimming, or football.
For some children, extra time to complete work, decreasing workloads (these children take much more time in completing their work as compared to peers, not because they do not know, but because of their problem of inattention), giving smaller assignments focusing on must-knows and use of word processors may help improve their performance and their self-esteem. Some schools may be open to use of these strategies. Only the Indian Certificate of Secondary Education Board allows for some of these accommodations, but these must be recommended only in conjunction with other treatments and must not be used as a sole measure.
In any case, every attempt should be made after obtaining consent to liaise with the school. As a minimum, it should be conveyed to the school teachers that ADHD is a valid diagnosis and use of certain environmental modifications and strategies will help the child. Every effort should be made to enlist their support. See “Liaising with the School” Section for detailed discussion.
[Table 12] summarizes the environmental modifications that can be instituted at home and school.
|Table 12: Environmental modifications to minimize distraction, improve attention, and channelize energy|
Click here to view
Parent training intervention
Individual or group parent training programs are generally skills based and aim at imparting such skills to parents that they are able to implement behavioral strategies effectively. Parents must be explicitly told that referral for parent training does not mean that their parenting is faulty; rather the training would help them in learning strategies, for particularly difficult and extraordinary situation that they are facing. Other significant members of the family may be involved in such programs if needed.
The clinician must remember while dealing with the parents and family that a parent might himself or herself have ADHD with its resultant attentional and organizational difficulties and impulsivity or may have other psychopathology (e.g., depression) that may hinder the effective implementation of the strategies. Furthermore, some families may be better suited for individual training. The indications for individual parental training include comorbid conduct problems or disorder, family psychopathology, intellectual disability in parent, language difficulties, or difficulties in therapeutic engagement due to any reason.
Most parent training programs are carried out over 8–10 weekly sessions if individual and 10–20 sessions if group training. It must cover psychoeducation, environmental modifications, effective communication methods, behavioral management strategies (may include token economy), anticipating and preparing for unstructured situations, and taking care of self and may include liaising with teachers. Environmental modifications specific to ADHD have been presented in detail in the earlier section. Effective communication includes effective ways of instructing (clear, short, long instructions simplified into steps), rephrasing statements, focusing on positives while communicating, decreasing critical comments, and establishing consistency between what is said and what is done (no empty promises or warnings regarding consequences). The behavioral principles used are setting of clear rules, consistency, use of immediate rewards, followed by use of delayed rewards contingent upon desirable behaviors, withdrawal of rewards or response cost contingent upon undesirable behaviors; rewards and cost being proportionate to the behavior. Consistency should be employed across time (i.e., a parent being consistent over time across situations) and across individuals (i.e., there must be consistency between both the parents; and also grandparents if applicable). Above all, parents must be encouraged to focus on their child's and their own strengths and inculcate healthy parent–child interactions. Parents must also be encouraged to appreciate their own and the child's efforts through regular positive feedback. Feedback should also be sought regularly from the parents, and difficulties faced by them in implementing the strategies must be addressed regularly. [Table 13] presents the components of a parent training intervention manualized at PGIMER, Chandigarh.
|Table 13: Components of PGIMER manual: “Parent training for families of children with attention-deficit/hyperactivity disorder”|
Click here to view
Cognitive behavior therapy
In case of older children and adolescents, who have benefited from environmental modifications and parent training and/or use of medications, but still have significant impairments in specific domains, cognitive behavior therapy may be considered. For example, there may be problems in peer functioning or social functioning or problems in academics due to poor time management. For example, cognitive behavior therapy may focus on enhancing social skills in dealing with peers, time management, problem-solving, dealing with and expressing feelings, and self-control and anger management.
Cognitive training may improve working memory, but it is not yet well researched if this translates into improved academic functioning.
The treatment should as far as possible be tailored to the individual needs based on current level of symptom severity and impairment, and improvements, if any gained by the nonpharmacological measures. Factors that may need to be taken into account include variations in bioavailability and pharmacokinetic profiles of different preparations so as to avoid reduced effects or excessive side effects, coexisting neurodevelopmental or psychiatric or physical disorders, specific treatment needs, and risk of drug misuse or diversion. Diversion occurs when someone in the patient's circle who has access to the medical uses it without prescription, usually for recreational purposes or to enhance performance.
Baseline assessment before starting a medication
Weight and height should be measured and plotted on the World Health Organization or Indian Association of Paediatrics weight-for-age and height-for-age growth charts, respectively along with body mass index. Baseline assessment of appetite, diet, and sleep should be done and recorded.
Specific medical and family history that takes into account contraindications for specific medications should be reviewed. This history must include that of exercise intolerance or shortness of breath during exercise that is excessive as compared to peers, or syncope or fainting episodes on exertion or in response to sudden noise or fright, congenital heart disease or previous cardiac surgery, rapid, regular palpitations that stop and start suddenly, or chest pain suggestive of cardiac origin. Family history of sudden young (<40 years of age) cardiac death should be specifically enquired into. A cardiologist's opinion should be sought before starting the medication if any of these are present. Heart rate and blood pressure must be measured in the patient at rest. The blood pressure must be measured using age-appropriate cuffs and plotted on age-adjusted percentile charts. Alternately, heart rate and blood pressure may be compared with the normal range for age. If the baseline heart rate is more than 100 beats/min or systolic or diastolic blood pressure is more than the 95th percentile, or more than normal for age, it should be repeated twice within 10 min. If there is persistent tachycardia (>100 beats/min) or systolic or diastolic blood pressure is >95th percentile, or there are signs of heart failure or a murmur is heard on auscultation, an electrocardiogram (ECG) should be done, and a cardiologist opinion should be sought. There is no recommendation for routine baseline ECG, except when a tricyclic antidepressant (TCA) is considered. TCAs are however third-line drugs and should be avoided due to their side effect profile.
History of seizures of any kind and of tics must be specifically looked for. Liver enzymes, i.e., alanine transferase and aspartate transferase levels, should be done at baseline if atomoxetine is to be prescribed. [Table 14] summarizes the baseline assessment before starting a medication.
Parents must be explained the effect of medications on the symptoms, i.e., which symptoms will improve with medications and which will not improve with medications. Parents also must be explained about the available options, possible side effects with different medications, and given a choice to select a specific agent.
The stimulant medications with maximum evidence for ADHD include methylphenidate, dexamphetamine, and lisdexamfetamine. Methylphenidate is the only stimulant available in India. There are several different formulations of methylphenidate available in the Indian market. These include immediate-release (IR) (short-acting), sustained/extended-release (intermediate-acting), and osmotic-controlled release oral delivery system, i.e., OROS (long-acting) preparations [Table 15]. Methylphenidate-IR has a relatively short half-life, with a duration of action of 1–4 h. Maximum drug concentration occurs at about 1–2 h after oral administration, and this is the time of maximum effect also. Due to short half-life, IR preparations need twice or thrice daily dosing. Sustained/extended-release preparations have a duration of action of about 6–8 h, while the OROS preparation has duration of action of 12 h. Due to their longer half-lives, the intermediate-acting (sustained preparations) and long-acting (OROS) preparations need single dosing in the morning and may improve adherence as compared to IR preparation. There is marked individual variability in dose-response relation, and optimal dose titration aiming at maximum response with minimal or acceptable level of side effects must be done for each individual patient.
|Table 15: Medications available in India for management of attention-deficit/hyperactivity disorder|
Click here to view
The nonstimulants that have evidence for ADHD in children and adolescents include atomoxetine, clonidine, guanfacine, tricyclic antidepressants, modafinil and bupropion, and desipramine. Out of these, clonidine extended-release and guanfacine are not available in India.
Atomoxetine is a selective noradrenaline reuptake inhibitor, taken as once daily dose in the morning. Some individuals may benefit by dividing the daily dose and taking it twice daily, once in the morning and second dose at late afternoon or early evening. Atomoxetine is metabolized by CYP2D6 enzyme; hence, poor metabolizers may have more side effects, and there are chances of drug-drug interactions. Atomoxetine has evidence of greater efficacy than other nonstimulant drugs. Clonidine is an alpha 2 noradrenergic agonist taken in 3–4 divided daily doses as extended-release clonidine is not available currently in India.
TCAs, modafinil, and bupropion are considered third-line drugs. TCAs are generally not recommended due to their side effect profile.
If a medication has to be started, the child and parents must again be apprised of the specific side effects, monitoring, and any precautions, as the case may be. In case of stimulants and atomoxetine, appetite suppression and sleep difficulties may become a concern in the initial part of the treatment itself. Hence, specific advice regarding meals and sleep hygiene may be given. In case of clonidine, parents must be specifically advised regarding the risk of rebound hypertension with abrupt discontinuation of the drug; hence, doses of clonidine should not be missed. Medications should be started at a low dose [as indicated in [Table 14]; and side effects and improvement must be monitored after each increment. Stimulants are schedule X drugs; retailers cannot sell without a license and except on and in accordance with the prescription of a registered medical practitioner and are supposed to retain a copy of the prescription for 2 years. The clinician must mention clearly the exact number of days, for which the prescription is given.
During the phase of dose titration, the child should preferably be seen every week/once in 2 weeks. The clinician must gauge improvement vis-a-vis side effects. Improvement may be rated on a structured scale or on a simple instrument such as CGI. If possible, ratings may be obtained from the teachers at 2–4 weekly intervals. Specific inquiries should be made regarding the onset of improvement noted after intake of medication (for example, about 60 min after the morning dose) and duration of such improvement (for example, till 11 am). Parents and teachers may report that the child is disruptive in the class during afternoons. This may be due to tiredness or wearing off of the drug's effects. Such reporting will aid the clinician to titrate the dose or change the dosing pattern.
Specific inquiries should be made regarding side effects. This should be done both from parents and the child. Some older children and adolescents report that they do not like the drug effect and feel they are not themselves. Such concerns may affect adherence to the medication and should be addressed. The child's sleep patterns and food intake should be asked about. Appetite suppression and reduced food intake may be a major concern for the parents. Weight should be measured on every visit during titration and plotted on the for-age charts.
Response to medications must be reviewed across different settings and domains of functioning. Specific inquiries should be made regarding side effects. The child's sleep patterns and food intake should be asked about. Weight should be measured on every visit during titration and thereafter every 3 months. Height should be measured every 3–6 months. Both weight and height should be plotted on the for-age charts and monitored over time. Heart rate and blood pressure should be measured on every visit. Stimulants may increase the pulse rate and blood pressure, while clonidine can cause orthostatic hypotension. Liver enzymes should be monitored periodically if atomoxetine has been started.
A 6-week trial of methylphenidate at an adequate dose if taken with good adherence may be considered as adequate. Time to response for atomoxetine is longer than that for stimulants. Hence, it may be continued at an adequate dose for around 12 weeks with good adherence for an adequate trial.
Improving medication adherence
Besides response to the medication and its tolerability, other important factors that may affect adherence are multiple dosing, stigma especially if the child needs to take a dose during the school hours, and perceptions of patients and families regarding medications and cost. Cost of the medication and that of multiple visits to the hospital during drug titration and for later follow-ups may be a major practical hindrance.
In case of inadequate adherence due to multiple dosing, sustained-release or OROS preparations may be prescribed. OROS preparations are relatively more expensive. A sustained-release preparation with additional IR doses as required may be another option. Ongoing discussions related to efficacy, side effects, and patient and family preferences are necessary and should be carried out regularly as far as possible.
Drug holidays are planned breaks in taking medications, usually during periods when the child is expected to have lesser demands for performance. These can be short, over weekends, or longer, during summer vacations. Drug holidays may reduce adverse events and give opportunities for improvement in appetite and catch up growth. During drug holidays, the symptoms may or may not worsen. Longer drug holidays also provide with opportunities to assess for ongoing need for medications. Weekend drug holidays are more appropriate for stimulant drugs, where such holidays do not cause any advertent effect such as rebound hypertension with clonidine. However, drug holidays increase the chances of nonadherence (unplanned discontinuation or missing of doses) during non “holiday” periods.
Discontinuation of medication
The need for continued medication should be reviewed at least once a year. The benefits, impact on functioning including academics, side effects, effects of missed doses, planned dose reductions, and periods of no treatment and any psycho-\social treatment in place and its effects as well as patient and family preferences are the factors to be taken into account. A few clinical signs that indicate that ADHD has remitted include lack of any need to adjust dose despite robust growth and lack of deterioration when a dose of stimulant medication is missed or able to concentrate during drug holidays. Consider trial periods of stopping or reducing the medication dose if benefit–risk analysis suggests that it may be appropriate. Vacations are probably a good time to attempt withdrawal of medications. However, parents should be advised to assign the child in some cognitively demanding tasks (such as solving math problems and reading a book) to confirm that improvements persist despite being medication-free.
Managing drug side effects
[Table 16] presents the side effects of ADHD medications, along with guidance on monitoring for and management of these side effects.
Managing sleep problems associated with attention-deficit/hyperactivity disorder
Behavioral problems such as bedtime resistance, sleep-onset delay, effect of psychiatric comorbidity, and sleep disorders may contribute to sleep difficulties in children with ADHD. It is suggested that pretreatment or baseline sleep patterns, including behavioral patterns around bedtime routines, be evaluated. Bedtime resistance including behaviors such as the child refusing to get ready for bed, refusing to remain in bed, or requiring a parent to be present at bedtime is often the result of parental difficulties in limit setting and managing behaviors. It is suggested that sleep hygiene measures and behavioral interventions for healthier bedtime routines be instituted. These may include avoiding evening naps, having a regular bedtime, calming bedtime routine, darkened room, comfortable bed and no loud noises that promote sleep, and avoiding electronic media or screen use in the evening and adults also not using screens in the bedroom. In individual cases, low-dose clonidine or melatonin (3 mg in children and 3–6 mg in adolescents) may be used for sleep-onset delay. Sleep studies including polysomnography are only indicated for specific sleep-related disorders and not routinely.
| Evidence|| |
In preschoolers, there is some evidence of short-term efficacy of stimulants; however, there are serious concerns regarding side effects, especially related to appetite and growth suppression. In children >6 years and adolescents, stimulants, atomoxetine and clonidine, have been shown to be significantly more efficacious than placebo. Stimulants have been shown to be superior to nonstimulants and have good short-term efficacy although evidence for long-term efficacy is inadequate. There is not adequate evidence of differences in efficacy or side effects between the different formulations of methylphenidate. The main advantage of longer-acting formulations over the short-acting is in single versus multiple dosing that may result in lesser stigma associated with taking a dose in school and better adherence. Among nonstimulants, atomoxetine has greater evidence of efficacy with effect sizes, though lower than stimulants, better than the other nonstimulants. There is evidence of efficacy for clonidine although effect sizes are smaller than that for atomoxetine. Among tricyclic antidepressants, desipramine has the largest evidence of efficacy, but the medication has considerable cardiac side effects.
In preschoolers, there is enough evidence for group and individual parent training interventions. In children >6 years and adolescents, there is evidence of efficacy for parent training interventions and in older children and adolescents for other psychosocial interventions also.
Comparing medication and psychosocial interventions
There is no robust evidence directly comparing medications with psychosocial interventions. In preschoolers, there is evidence of efficacy for both medications and psychosocial interventions, with more concerns about side effects with the medications. In children >6 years of age and adolescents, there is evidence of efficacy for both medications and psychosocial interventions. There is some evidence of possible differential effects of the two modalities, with the drug being more efficacious for the core symptoms whereas nonpharmacological interventions being more efficacious in improving associated behavioral problems and functioning. Although the effect sizes for medications, especially stimulants are greater than those for psychosocial interventions, it is probable that this is because of the outcome measures studied; ADHD symptom-specific outcomes versus more generic outcomes regarding behavioral problems and functioning.
There is no evidence that combination of two medications offers any advantage over a single medication. In addition, there are more side effects and hence should be avoided. Combination of medication with psychosocial intervention has been found to be more efficacious than psycho-social intervention alone. Adding psychosocial intervention to the medication treatment may offer specific benefits and so must be instituted when indicated. Besides evidence of possible differential effects of the two modalities, there is also some evidence that addition of psychosocial interventions may facilitate dose reduction and discontinuation of medication on follow-up.
Diet and exercise
It is suggested that all children and adolescents be advised regarding need for nutritious and balanced diet and physical exercise.
Exclusion of food preservatives and additives and elimination or oligoantigenic (few foods) diets
There is not enough evidence for special diets such as exclusion of food additives and preservatives or elimination of several potential antigens as in the oligoantigenic diets as stand-alone treatments in the management of ADHD. There are limited evidence of short-term benefits and not enough evidence of long-term effectiveness or harms of elimination diets. If it is suspected that specific foods increase the symptoms, it is suggested that parents be advised to maintain detailed diet diaries and any elimination of specific food be attempted only in consultation with an expert dietician. It may take weeks to months for tailoring an oligoantigenic diet through series of re-introduction of foods and requires close collaboration between the dietician, clinician, and the family and patient. IgG blood tests are not helpful in selecting foods for elimination. The clinical utility of dietary interventions may be explored in individual cases, bearing in mind difficulties in practical implementation such as preparation of special foods in a household with several members, parents' control over child's diet, motivation of child and family, as well as expenses toward preparation of additive-free or antigen-free foods.
Omega fatty acids and nutritional supplements
There is inconclusive evidence for the use of omega fatty acids or any micronutrient or nutritional supplements for the treatment of ADHD, and hence, it is suggested that such dietary supplements may not be prescribed for this purpose routinely till further good-quality evidence emerges.
Although small studies indicate that neurofeedback may have some positive effects on core symptoms and neuropsychological functions, well-designed studies and meta-analysis have have failed to show the same. Overall, there is not adequate evidence to support neurofeedback for treatment of ADHD.
| Liaison With School|| |
It is suggested that liaison with the school be a continual activity. First and all subsequent contacts with the school should be after parental and patient's consent and as far as possible contact should be made through the parents. It is sound clinical practice to acknowledge the school's strengths while dealing with the index child, taking teacher's observational report and follow-up feedbacks. Teacher reports and parent reports may give insights into different areas of impairment and in different settings. A good alliance with the teachers will set the stage to communicate the diagnosis and that it is a valid disorder and to suggest environmental modifications that a teacher can easily implement in the classroom. Efficient and sensitive teachers do encourage these children to exploit their other potentials and use verbal reinforcement effectively, while minimally using punishment. These children often are bullied or are bullies themselves, and school intervention can be very helpful in either case. Besides clinicians liaising with the school, parents may be advised to liaise with the child's teachers and use the parent–teacher daily report cards. These report cards aid in implementing the behavior principles more consistently and across the two settings.
| Steps in Managing Attention-Deficit/hyperactivity Disorder|| |
Factors determining the steps in management of attention-deficit/hyperactivity disorder
The evidence for medications is limited in preschoolers, whereas there are genuine concerns regarding the side effects of the medications. There is enough evidence for group and individual parent training interventions. Keeping these in mind, preschoolers must first be offered psychosocial interventions.
In children >6 years of age and adolescents, there is evidence of efficacy for both medications and psychosocial interventions. Medications appear to be more efficacious in improving the core symptoms of ADHD and psychosocial interventions in improving associated behavioral problems and functioning in specific domains. In mild ADHD, environmental modifications usually suffice alone; while in severe ADHD, medications may be necessary. In the latter case, following some response with the medication, psychosocial interventions may be indicated for specific problems or impairments in specific domains. In case of moderate ADHD, parent training where available must be offered first.
Besides the evidence for efficacy and side effects, and severity of ADHD, the other important factors that determine the strategies in managing ADHD include comorbidities, current needs, patient and family's preferences, affordability, and availability. [Table 17] lists the factors determining the steps in the management of ADHD.
|Table 17: Factors determining the steps in management of attention-deficit/hyperactivity disorder|
Click here to view
Steps in management of attention-deficit/hyperactivity disorder
[Figure 1] presents the algorithm for managing ADHD. It is expected that the plan and steps may have to be tailored to suit the needs of an individual patient. Psychoeducation and support to the child and family must as far as possible be provided to all individuals. Medication is not the first line of management in preschoolers and those aged less than 6 years as there are concerns regarding tolerability and safety. Furthermore, it is often difficult to differentiate a difficult temperament from ADHD in toddlers. Parent training interventions that include environmental modifications as well as behavioral management may be offered instead. The training may be given as group training or individual training. The clinician must consider addressing any factors that may hinder the effective implementation of the parent training intervention.
|Figure 1: The algorithm for managing attention-deficit/hyperactivity disorder|
Click here to view
For school-aged children and adolescents, it is suggested that environmental modifications be advised first. Despite the implementation of environmental modifications or in cases where the severity is so marked that such implementation is quite difficult, choose the next line of management based on the severity. In children with mild-to-moderate level of severity, offer parent training and school interventions. If the response is not good or parent training intervention is not available, and severity is at least of moderate level, offer medications. If ADHD is severe, medications must be offered. The sequencing of medications considering response, contraindications, side effects, affordability, and availability is preferably stimulant followed by atomoxetine followed by clonidine.
For all individuals who respond on a given treatment, continue with the same, along with periodic review and monitoring. In children and adolescents who have responded on medication, however, still have impairments in a specific domain, offer additional focused psychosocial intervention. For example, an adolescent having impairments in peer functioning offers social skills training. In case of response to a psychosocial intervention, continue with periodic booster sessions and monitoring.
In case of inadequate response on medication, check for nonadherence. Ensure adherence after addressing the child and family's concerns regarding the medication, these may include side effects, cost, and stigma. If child is adherent on the medication, optimize the dose while monitoring for side effects. If despite an adequate trial, there is inadequate response, consider changing the drug. Family may prefer psychosocial intervention following a failed medication trial; in that case, it must be offered if available after again discussing the benefits and risks of each modality of treatment. If there is inadequate response after adequate medication trials, review the diagnosis, manage comorbidities (for example, conduct disorder), may add parent training intervention. In case of inadequate response following parent training intervention, first check for and address adherence to the interventions. If despite this, there is inadequate response, and offer medication alone or in combination with the psycho-social intervention. [Table 18] lists out the factors related to inadequate response to pharmacological or nonpharmacological intervention.
|Table 18: Factors related to inadequate response to pharmacological or nonpharmacological interventions|
Click here to view
Besides the medication or parent training and other child-focused psychosocial interventions, ongoing liaison with the school must be carried out with consent of child and parents. School liaison strategies must be attempted. Review of teacher-implemented environmental modifications and behavioral management strategies must be made periodically, along with teacher reports regarding child's problems and progress [Figure 1].
Review and discontinuation of treatment
The clinician must perform ongoing reviews regarding improvement, tolerability, and needs of the child and family. The management plan may be altered in accordance with changing needs as outlined in earlier sections.
Further, the clinician must review the need for ongoing treatment at least once a year. For this, response to treatment, functioning in various domains, and maintenance of response despite periods of planned or unplanned discontinuation of treatment must be considered. As during initial assessment, assessment of symptoms and functioning at this stage must involve multiple informants (preferably, must involve teachers) and must be done across settings. The child and family must be involved in discussions regarding possibility of discontinuation and risks and benefits thereof, including chances of relapse, though definitely not inevitable and improvement in side effects. Discontinuation must be attempted during low-stress periods such as during vacations. Discontinuation of medications has been dealt with in detail in an earlier section. In case of psychosocial intervention, it is expected that some benefits may persist beyond the training programs. However, booster sessions may be required or focused strategies such as life skills or time management may be required. In case a child is on drug and nondrug treatment, the former may be discontinued first. The children and adolescents and their families must be advised ongoing reviews despite discontinuation of treatment. The clinician must monitor for relapse of symptoms or any impairments in functioning that need to be addressed.
| Special Circumstances|| |
In case of comorbid tic disorder, anxiety disorders, obsessive–compulsive disorder, and ASD, the same medication may be started as for children and adolescents without any comorbidity. However, drug titration must be slower and special attention should be paid to side effects. Clonidine or atomoxetine may be a good choice in case of comorbid tic disorder; while atomoxetine may be a good choice in case of comorbid anxiety disorder although there is no good evidence for avoiding methylphenidate.
In case of children with comorbid intellectual disability or ASD, tolerability is an important consideration. Some children with developmental disabilities experience irritability, withdrawal or agitation, and apparent worsening of symptoms. In such children, the diagnosis of ADHD should be revisited and the medication should be stopped. A nonstimulant medication may be started.
In case of psychosis or bipolar disorder coexisting with ADHD, the psychosis or mood disorder should be treated first, and after resolution of the symptoms, a review of diagnosis of ADHD should be made. The clinician should assess the need for medication and then may start a stimulant or a nonstimulant drug weighing the risks and benefits in the individual case and considering drug interactions.
In case of comorbid depression, the clinician must assess the severity of depression, presence of suicidal attempts or strong suicidal intent, and contribution of depressive symptoms to the overall global clinical severity. If the any of these are present, depression should be treated first. In case of severe depression or suicidal ideas or attempts, inpatient management may be warranted depending on the individual circumstances. On the other hand, if depression is not severe with mild neurovegetative symptoms, suicidal ideas but without strong intent and ADHD symptoms are thought to contribute more than depressive symptoms to overall clinical severity, and ADHD must be treated first. Often, the depressive symptoms and dysphoria may be related to the ADHD and resolve with effective treatment of ADHD.
In case of comorbid substance dependence, treatment of ADHD and substance dependence should be instituted simultaneously. The clinician must assess the risk of medication misuse and diversion. If this risk is high, a nonstimulant may be used.
If comorbid conduct disorder or oppositional defiant disorder is present, parent training directed toward the behavioral problems in addition to ADHD focused parent training should be commenced. Further, risk of medication misuse and diversion should be assessed and a nonstimulant drug may be started. Risperidone in low doses may be started particularly for aggression. Refer to Clinical Practice Guidelines (CPG) on Conduct Disorder for its management.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th
ed. Washington, D.C: American Psychiatric Association; 2013.
Barkley RA. Taking Charge of ADHD: The Complete, Authoritative Guide for Parents. New York: Guilford Press; 2005.
Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al.
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:179-203.
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Canadian ADHD Practice Guidelines. 3rd
ed. Toronto ON: CADDRA; 2011.
Catalá-López F, Hutton B, Núñez-Beltrán A, Page MJ, Ridao M, Macías Saint-Gerons D, et al.
The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 2017;12:e0180355.
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al.
Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013;54:227-46.
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al.
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry 2018;5:727-38.
Cortese S, Vincenzi B, Angriman M. Identifying and managing sleep disorders associated with ADHD. Neuropsychiatry 2012;2:393-405.
Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, et al.
Neurofeedback for attention-deficit/hyperactivity disorder: Meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 2016;55:444-55.
Fung DS, Lim CG, Wong JC, Ng KH, Cheok CC, Kiing JS, et al.
Academy of medicine-ministry of health clinical practice guidelines: Attention deficit hyperactivity disorder. Singapore Med J 2014;55:411-4.
Gautam S, Batra L, Gaur N, Meena PS. Clinical Practice Guidelines for the Assessment and Treatment of Attention-Defi cit/Hyperactivity Disorder. Ind J Psychiatry 2008. Available from: http://www.indianjpsychiatry.org/cpg2008.asp
. [Last accessed on 2018 Dec 20].
Gillies D, Sinn JK, Lad SS, Leach MJ, Ross MJ. Polyunsaturated fatty acids (PUFA) for attention defi cit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2012;(7):CD007986.
Maia CR, Cortese S, Caye A, Deakin TK, Polanczyk GV, Polanczyk CA, et al.
Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD. J Atten Disord 2017;21:3-13.
National Institute for Health and Care Excellence. Antisocial Behaviour and Conduct Disorders in Children and Young People: Recognition and Management. London: National Institute for Health and Care Excellence; 2013.
National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder in Children and Young People: Clonidine. London: National Institute for Health and Care Excellence; 2013.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder (update). Evidence Reviews for Information and Support for People with ADHD. Evidence Review. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder (update). Evidence Reviews for Pharmacological Efficacy and Sequencing Pharmacological Treatment. Evidence Review. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder (update). Evidence Reviews for Safety of Pharmacological Treatment. Evidence Review. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder (update). Evidence Reviews for Efficacy of Non-Pharmacological Treatment and the Impact of Adverse Events Associated With Non-pharmacological Treatments of ADHD. Intervention Evidence Review. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder (update). Evidence Reviews for Combined Pharmacological and Non-Pharmacological Treatments Review. Intervention Evidence Review. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder (update). Evidence Reviews for Adherence to Treatment (Pharmacological and Non-Pharmacological); Evidence Review. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder (update). Evidence Reviews for the Principles for Discussion when Starting, Adjusting and Discontinuing Pharmacological Treatment for ADHD. Evidence Review. London: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Attention defi cit hyperactivity disorder (update). Withdrawal from Pharmacological Treatment and Drug Holidays. Evidence Review. United Kingdom: National Institute for Health and Care Excellence; 2018.
National Institute for Health and Care Excellence. Sleep disorders in children and young people with attention deficit hyperactivity disorder melatonin. Evidence summary. London: NICE; 2013.
National Institute for Health and Care Excellence. The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults. London: NICE; 2009.
National Institute for Health and Care Excellence. Attention Deficit Hyperactivity Disorder Clinical Guideline Addendum 72.1 Methods, Evidence and Recommendations. London: NICE; 2016.
Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2018;6:CD007990.
Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2014;(9):CD006997.
Pelsser LM, Frankena K, Toorman J, Rodrigues Pereira R. Diet and ADHD, reviewing the evidence: A systematic review of meta-analyses of double-blind placebo-controlled trials evaluating the efficacy of diet interventions on the behavior of children with ADHD. PLoS One 2017;12:e0169277.
Shah R, Sharma A, Grover S, Sachdeva D, Chakrabarti S, Avasthi A. PGIMER Manual: Parent Training for Families of Children with Attention Deficit/Hyperactivity Disorder. Chandigarh: Department of Psychiatry, Postgraduate Institute of Medical Education and Research; 2018.
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al.
Nonpharmacological interventions for ADHD: Systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013;170:275-89.
Sonuga-Barke E, Taylor E. ADHD and hyperkinetic disorder. In: Thapar A, Pine DS, Leckman JF, Scott S, Snowling MJ, Taylor EA (Eds). Rutter's Child and Adolescent Psychiatry. 6th
ed. USA: Blackwell Publishing Limited; 2015.
Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al.
European clinical guidelines for hyperkinetic disorder – First upgrade. Eur Child Adolesc Psychiatry 2004;13 Suppl 1:I7-30.
Taylor E, Sonuga-Barke E. Disorders of attention and activity. In: Rutter M, Bishop D, Pine D, Scott S, Stevenson JS, Taylor EA, et al
, editors. Rutter's Child and Adolescent Psychiatry. 5th ed. USA: Blackwell Publishing Limited; 2008.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
Young S, Amarasinghe JM. Practitioner review: Non-pharmacological treatments for ADHD: A lifespan approach. J Child Psychol Psychiatry 2010;51:116-33.
Dr. Ruchita Shah
Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh
Source of Support: None, Conflict of Interest: None
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8], [Table 9], [Table 10], [Table 11], [Table 12], [Table 13], [Table 14], [Table 15], [Table 16], [Table 17], [Table 18]